...
首页> 外文期刊>Mycopathologia >In Vitro Activity of Berberine Alone and in Combination with Antifungal Drugs Against Planktonic Forms and Biofilms of Trichosporon Asahii
【24h】

In Vitro Activity of Berberine Alone and in Combination with Antifungal Drugs Against Planktonic Forms and Biofilms of Trichosporon Asahii

机译:单独的Berberine的体外活性,并与抗真菌药物的抗真菌药物组合,并肌肤朝鲜孢子的生物膜

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Trichosporon asahii (T. asahii) is an opportunistic pathogen that can cause life-threatening infections in immunocompromised patients, with high mortality rates up to 80% despite treated with antifungal drugs. The biofilms-forming ability of T. asahii on indwelling medical devices may account for the resistance to antifungal drugs. Berberine (BBR) has been demonstrated to have antifungal activity and synergistic effects in combination with antifungal drugs against pathogenic fungi. In the present study, the in vitro activities of BBR alone or combined with fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), caspofungin (CAS) and amphotericin B (AMB) against planktonic forms and biofilms of 21 clinical T. asahii isolates were evaluated using checkerboard microdilution method and XTT reduction assay, respectively. The fractional inhibitory concentration index (FICI) was used to interpret drug interactions. BBR alone did not exhibit significant antifungal activities against both T. asahii planktonic cells (MICs, 32 -> 128 mu g/ml) and T. asahii biofilms (SMICs, > 128 mu g/ml). However, BBR exhibited synergistic effects against T. asahii planktonic cells in combination with AMB, FLC and CAS (FICI aecurrency> 0.5) and exhibited synergistic effects against T. asahii biofilms in combination with AMB and CAS (FICI aecurrency> 0.5). BBR/ITC and BBR/VRC combinations yielded mainly indifferent interactions against T. asahii planktonic cells. BBR/FLC, BBR/ITC and BBR/VRC combinations also yielded indifferent interactions against T. asahii biofilms. Our study highlights the therapeutic potential of BBR to be used as an antifungal synergist in combination with antifungal drugs against T. asahii infections, especially BBR/AMB combination. Further in vivo studies are needed to validate our findings.
机译:Trichosporon Asahii(T.Asahii)是一种机会主义病原体,可导致免疫疗效危及危及危及免疫患者的感染,尽管用抗真菌药物治疗,但仍有高达80%的死亡率高达80%。 T.Asahii对留置医疗装置的生物膜形成能力可能考虑对抗真菌药物的抗性。 Berberine(BBR)已经证明具有抗真菌活性和协同作用与抗真菌药物的抗真菌药物组合。在本研究中,单独的BBR或与氟康唑(FLC),伊丙唑(ITC),伏立康唑(VRC),Caspofungin(CAS)和两性霉素B(AMB)的体外活性对抗氏菌属形式和21例临床T.使用棋盘微稀释方法和XTT还原测定分别评估Asahii分离株。分数抑制浓度指数(FICI)用于解释药物相互作用。单独的BBR没有对T.Asahii氏菌氏菌细胞(MICS,32->128μmg/ ml)和T.Asahii生物膜(SMICS,>128μg/ ml)表现出显着的抗真菌活性。然而,BBR与Asahii氏菌细胞与AMB,FLC和CAS(FICI AE<汇率> 0.5)表现出对T.Asahii氏菌氏菌细胞的协同作用,并与ASAHII生物膜与AMB和CAS(FICI AE< COMPECTION)表现出对T.Asahii生物膜的协同作用。 )。 BBR / ITC和BBR / VRC组合产生了针对Asahii氏菌细胞的无关紧要的相互作用。 BBR / FLC,BBR / ITC和BBR / VRC组合也产生了针对Asahii Biofilms的漠不关心的相互作用。我们的研究突出了BBR的治疗潜力,用作抗真菌和抗真菌药物的抗真菌增效剂,尤其是BBR / AMB组合。进一步在体内研究需要验证我们的研究结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号